REGISTER: Hear how PetroTal (PTAL) is increasing oil & gas production in Peru. Find out more at the focusIR Feb Investor Webinar. Sign up here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksXps Pensions Share News (XPS)

Share Price Information for Xps Pensions (XPS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 404.00
Bid: 399.00
Ask: 400.00
Change: 14.00 (3.59%)
Spread: 1.00 (0.251%)
Open: 390.00
High: 404.00
Low: 385.00
Prev. Close: 390.00
XPS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors buy following Proximagen deal

Thu, 05th Aug 2010 16:51

Three directors in AIM-quoted biotech sector consolidator Proximagen have added to their holdings following the company's deal with BrainCells Inc for its sabcomeline programme.The Proximagen share price was flat yesterday but the news of the share buying sparked it into life and it ended up 16.5p at 100p. Chief executive Ken Mulvany, finance director James Hunter and non-exec Michael Ashton each bought 15,000 shares at an average price of 84p a share. The shares were bought on 4 and 5 August. Mulvany owns 1.39% of Proximagen, while Hunter owns 20,000 shares and Ashton 41,384 shares. BCI will pay Proximagen an up-front fee and milestone payments worth up to $51m for sabcomeline, as well as royalties on sales. However, most of this cash will not be paid for years and that assumes the clinical trials go as planned. BCI will own the worldwide rights to sabcomeline, which was acquired by Proximagen in February when it paid 6p a share for AIM-quoted Minster Pharmaceuticals, which valued the drug developer at £4.3m. Minster came with £3.5m in cash. Sabcomeline is a treatment for cognitive decline in schizophrenia, which was licensed from GlaxoSmithKline. This is not a core area for Proximagen, which focuses on treatments for neurological conditions. BCI will be responsible for milestone and royalty payments to GSK, as well as the clinical development, regulatory filing and commercialisation of the drug. A phase II trial is planned. In June 2009, Proximagen raised £49m at 140p a share. Proximagen still had £51m in cash and bank deposits at the end of May 2010. There was an outflow from operations of £3.5m in the year to May 2010. Proximagen is valued at £57.4m so there is little upside from its drugs recognised in the share price. Prior to today's share price rise the company was trading at below cash. Minnesota-based Upsher-Smith agreed a similar deal to the BCI one for PRX1, which is a programme for the symptomatic treatment of Parkinson's disease based on an improved version of L-Dopa - a known treatment. The upfront and milestone payments alone could come to $232m (£117m). Again most of these payments are a long way off, although Upsher-Smith did invest $6m at 227p a share in October 2008. Top Director BuyseXpansys (XPS) Director name: Mr Graham DawberAmount purchased: 339,000 @ 7.25p Value: £24,578Proximagen Group (PRX) Director name: Mr James Douglas HunterAmount purchased: 15,000 @ 84.00p Value: £12,600Proximagen Group (PRX) Director name: Mr Kenneth MulvanyAmount purchased: 15,000 @ 84.00p Value: £12,600Proximagen Group (PRX) Director name: Mr Michael AshtonAmount purchased: 15,000 @ 84.00p Value: £12,600MS International (MSI) Director name: Mr David PyleAmount purchased: 10,000 @ 121.50p Value: £12,150Top Director SellsHeavitree.A (HVTA) Director name: Mr Rodney J GlanvilleAmount sold: 7,000 @ 170.00p Value: £11,900
More News
16 Oct 2024 14:40

London close: Stocks rise on fresh rate cut hopes

(Sharecast News) - London's equity markets finished higher on Wednesday as investors reacted positively to a significant drop in UK inflation, which reached its lowest point in over three years.

Read more
16 Oct 2024 08:43

XPS Pensions upbeat on strong half-year trading

(Sharecast News) - XPS Pensions reported strong trading for the six months ended 30 September on Wednesday, with revenue from continuing operations up 23% year-on-year.

Read more
14 Oct 2024 15:58

UK earnings, trading statements calendar - next 7 days

Read more
16 Sep 2024 12:20

UK dividends calendar - next 7 days

Read more
29 Aug 2024 16:12

UK shareholder meetings calendar - next 7 days

Read more
15 Aug 2024 14:23

UK dividends calendar - next 7 days

Read more
21 Jun 2024 10:09

SMALL-CAP WINNERS & LOSERS: Gulf Keystone declares dividend

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
21 Jun 2024 09:28

LONDON BROKER RATINGS: Barclays cuts Ryanair and Wizz Air

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday:

Read more
20 Jun 2024 12:33

XPS Pensions celebrates rising earnings in "really pleasing" year

(Alliance News) - XPS Pensions Group PLC shares rose on Thursday after it announced "another year of record growth", and increased its annual dividend.

Read more
20 Jun 2024 12:28

XPS Pensions Group reports year of strong growth

(Sharecast News) - XPS Pensions Group reported a 21% increase in group revenue in its final results on Thursday, to £196.6m.

Read more
20 Jun 2024 10:29

SMALL-CAP WINNERS & LOSERS: Speedy Hire wins Amey deal; XPS rises

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
13 Jun 2024 16:05

UK earnings, trading statements calendar - next 7 days

Read more
11 Jun 2024 09:57

LONDON BROKER RATINGS: Morgan Stanley cuts Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:

Read more
5 Jun 2024 20:17

TOP NEWS: Ocado checks out of FTSE 100 as Vistry and Darktrace join

(Alliance News) - Ocado Group PLC has been relegated from the FTSE 100 in the latest quarterly reshuffle which sees promotions for technology firm Darktrace PLC, housebuilder Vistry Group PLC and property company LondonMetric Property PLC.

Read more
29 May 2024 07:18

Darktrace, Vistry Group up for promotion to FTSE 100

LONDON, May 29 (Reuters) - Cybersecurity company Darktrace and homebuilder Vistry Group are two candidates for inclusion in the FTSE 100 in the upcoming quarterly review, index provider LSEG said in a note released late on Tuesday.

Read more

Track Your Investments

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.